# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatme...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:PTN) with a Buy and maintains $17 price target.
The Dow Jones index closed slightly lower on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...
Palatin Technologies unveils Phase 3 PL9643 MELODY-1 trial results for dry eye disease treatment, showcasing statistically sign...